March 21, 2025 11:38 AM EDT
Pharma
FDA+

FDA ap­proves No­var­tis’ Fab­hal­ta in an­oth­er rare kid­ney dis­ease

Lei Lei Wu

News Reporter

No­var­tis’ Fab­hal­ta notched an­oth­er FDA ap­proval, this time in adults with an ul­tra-rare kid­ney dis­ease called C3 glomeru­lopa­thy.

Fab­hal­ta is the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Trump think tank res­ur­rects in­ter­na­tion­al drug pric­ing mod­el to go af­ter 'glob­al free­load­ing'

Ex­clu­sive: Roivant-backed Van­tAI de­buts AI mod­el Neo-1, tak­ing ‘the big next step’ af­ter Al­phaFold 3

Teenag­er dies af­ter re­ceiv­ing Sarep­ta ther­a­py; Im­muno­vant gets Phase 3 win, but shifts fo­cus; Al­ny­lam’s big mo­ment; ...

John­son & John­son ear­marks $55B to boost US ca­pac­i­ty 

As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

A service from the Financial Times